Easier treatment schedule for multiple myeloma falls flat before it starts
NCT ID NCT06348147
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test a less intense version of a standard four-drug combination (Dara-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if giving one drug (bortezomib) once a week instead of twice could still work well while causing fewer side effects like nerve damage. However, the trial was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd)
- What this could lead to
- If successful, this could show that a less frequent dosing schedule works as well as the standard, making treatment more convenient and reducing nerve damage risk.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data was collected. The approach remains unproven, and the standard schedule is still the only evidence-based option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOLOGOUS STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27516, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time CAR-T therapy outsmart myeloma and replace lifelong treatment?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?